Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.
The global vaccines market is growing at nearly 10%, far outpacing drugs and devices. Improvements in national immunization programs, innovative partnerships between public and private vaccine stakeholders, pricing leverage, and advances in vaccine technology are driving the growth, according to IMS consultant Kevin Fitzpatrick.
Speaking at a New York Pharma Forum event Oct. 16, Fitzpatrick identified two salient characteristics of the vaccine market that set it apart from drugs and devices
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
